

Company Profile



Company Profile

Securities code: 7747
Prime of Tokyo Stock Exchange
Premier of Nagoya Stock Exchange

Company Name	ASAHI INTECC CO., LTD.	Treffiel of Hagoya Stock Exchange
Head Office	3-100 Akatsuki-cho, Seto-shi, Aichi, Japan	
Representative	Kenji Miyata, President & CEO	
Date of Establishment	July 8, 1976 (Currently, the 50th term)	
Business Operations	Development, manufacturing and sale of medical dependence of medical dependence of ultra-fine wire ropes, terminal processed products, etc.	
Capital	18,860 Mil. Yen	
Number of Employees	1,196(Asahi Intecc only), 9,473(Total)	
Related Company	18 Consolidated subsidiaries, 7 Non-consolidated s	subsidiaries _{ж 1}
R&D base	Japan, Thailand, US	
Manufacturing base	Thailand, Vietnam, Philippines, China _{×2}	
Sales base	Japan, US, Netherlands, France, Germany, Italy, Ru Hong Kong, Singapore, Thailand, India, UAE, Brazil	

X1 Non-consolidated subsidiaries NITTA M&T and NITTA MOLD became consolidated subsidiaries in FYE June 2030.

<As of Jun. 2025>



^{*2} The Chinese factory is scheduled to begin operations around December 2030.

Global Network — R&D/Production

(Coexistence of Japan & Overseas)







China:

Asahi Inda Medical Equipment (Nanning) Co., Ltd.

Scheduled to begin operations around December 2030.

GLOBAL HEADQUARTERS AND R&D CENTER (Product R&D

THAILAND:

ASAHI INTECC THAILAND CO., LTD.

[JAPAN] R&D/Prototype





TOYOFLEX CEBU CORPORATION




VIETNAM: ASAHI INTECC HANOI CO., LTD.

[OVERSEAS] **Production bases**

Japan conducts R&D and prototyping; mass production takes place in overseas factories.



(Reference) Main Sales Bases



(Reference) Development of R&D System Optimized for Global Expansion



Tohoku R&D Center









R&D-type company in the US ASAHI Medical Technologies, Inc. (Former name : Retro Vascular, Inc.)

State-of-the-art R&D

R&D for the US

ASAHI INTECC USA, INC.





Production Technology Development

ASAHI INTECC THAILAND CO., LTD.



CDMO

Rev. 1 Engineering, Inc.



Material Development

Osaka R&D Center



Resin Development

Shizuoka R&D Center



Advanced technology development

Tokyo R&D Center





Business Fields and Divisions

■ FYE June 2025

Revenue 120,025Mill. Yen

Operating income 30,079Mill. Yen



Industrial Field (approx. 4%)


Device Division

(Medical Components / Industrial Components)



Main Products of Device Division (Industrial Components)

- Develop, manufacturing and sales of precision stainless steel wire rope (less than 2mm diameter)
- Market
 - Rope: Automobile, construction and fishing industries
 - Terminal fitted: office automation, baby strollers, machineries, accessories, game consoles
 - Charge wire: office automation, air cleaners, etc.



Wide Range of Applications from Most-advanced Devices to Household Goods

GLOBERIDE, Inc. Fishing wire



Golf shoes wire



Air-conditioner with filter cleaning function



Smoke exhaust system



Copier driving wire




Stroller



Accelerator wire










Main Products of Medical Division (OEM), Device Division (Medical Components)

- Medical Division (OEM Supplies)
 Tube and various types of guide wires, etc., used for endoscopy or treatment devices
- COMET I Integrated Acolors whe design excertoes with floation Scientific and integrated absolute which allowed the floating account of the floating ac

FFR Guide Wire For Boston Scientific




ROTA Wire For Boston Scientific

Device Division (Medical Components)
Hollow cable tube, Stainless steel rope, other medical device components




Wire rope/tube Example: endoscopic accessory



ACT ONE



Main Products of Medical Device




Our main product at 48.2% (FYE June 2025) of Revenue




PCI (Percutaneous Coronary Intervention)-1

- Therapy for coronary artery disorder (angina, myocardial infarction)
- Recover the blood flow after dilatation of stenosed lesion
- Treatment through femoral or radial artery without laparotomy and thoracotomy to minimize the mental and physical burden on patients.



PCI (Percutaneous Coronary Intervention) -2

Essential Devices of PCI Treatment (Three Sacred Treasures)




PCI (Percutaneous Coronary Intervention)-3

For PCI treatment to be successful, the PCI guidewire must reach the affected area


1 PCI GW Advancement

Small size tube called PCI Guiding Catheter inserted in blood vessel. Advance PCI GW inside of this tube.




3 PCI Balloon Catheter dilatation

Dilate Balloon, then enlarge the blood vessel.




2 PCI Balloon Catheter Tracking


Along with PCI GW, PCI Balloon Catheter trucked over PCI GW to the point of the narrowed portion of vessel.



4 PCI Balloon Catheter pulled out

After Narrow portion enlarged then blood flow to recover.








PCI (Percutaneous Coronary Intervention)-4

Comparatively easy lesions



Lesions with high difficulty



Advantage of Our PCI Guide Wire

High transmissibility of rotation(Torquability)



Tip flexibility(Safe operation)

Doctors manipulate the wire and try to transfer the feeling of finger tip to the distal end of wire.

Source of competitiveness: 4 core technologies

Integrated production system handling materials down to the finished products

Control of hardness and diameter



Wire drawing technology

Wire forming technology

430



Micron-level molding

Rotation following capacity



Torque technology


Resin coating technology

Ultra-thin film coating



Our Company's Flagship CTO Treatment

Implementation of PCI Treatment in CTO Cases



In the era when the Japanese market depended on imports for PCI GW, Japanese KOL requested major manufacturers to make a wire for CTO PCI but were turned down.

※KOL(Key Opinion Leader)


··· A physician with influence over the direction of PCI.

PCI GW for CTO Procedures (1995)


Aggressive expansion of CTO cases via minimally invasive procedures



Our Strength and Feature "Competitive Power in Medical Devices" Based on "High Technology for Raw Material"



Our Strength and Feature Merits of Segmental Structure (fusion/combination/circulation)



Caution Regarding Information Presented

All forward looking statements contained herein, including revenue forecasts, outlooks, and strategic plans, are based on the best currently available data; however, risk and uncertainty are involved in these statements.

Please note that actual results may differ greatly from plans presented here.

[IR contact]

Asahi Intecc Co., Ltd. corporate strategic office

TEL 0561-48-5551 URL https://www.asahi-intecc.co.jp/en

